Birch allergy vaccine - Circassia
Latest Information Update: 17 Nov 2016
At a glance
- Originator Circassia
- Class Allergens; Antiallergics; Tree pollen allergy immunotherapies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase II Seasonal allergic rhinitis
Most Recent Events
- 01 Jul 2016 Circassia completes a phase-II clinical trial in Seasonal allergic rhinitis in Canada (unspecified route)
- 01 Jul 2015 Phase-II clinical trials in Seasonal allergic rhinitis in Canada (unspecified route)